Phase 2 Study of 9-ING-41, a Glycogen Synthase Kinase 3 Beta (GSK 3β) Inhibitor, Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma

9-ING-41 is a small molecule potent selective GSK-3β inhibitor with antitumor activity. This study investigates 9-ING-41 in combination with carboplatin chemotherapy in patients with incurable, recurrent or metastatic salivary gland carcinomas (SGC). Patients with advanced SGC (including all histologic subtypes and adenoid cystic carcinoma [ACC]) will receive 9-ING-41 intravenously (IV) along with carboplatin IV at standard dosing together on Day 1, and 9-ING-41 alone on Day 4 of a 21-day cycle. Participants will be enrolled to two histologic cohorts: Cohort 1 will be comprised of those with ACC, and Cohort 2 will include patients with non-ACC SGC (or all other salivary gland cancer histologies). Treatment will continue until progression of disease, death, or discontinuation of therapy for any reason.

开始日期2030-12-18

申办/合作机构

Actuate Therapeutics, Inc.

NCT06896188

/ Not yet recruiting临床1期IIT

A Phase Ib Study of 9-ING-41 (elraglusib), a Glycogen Synthase Kinase 3-beta (GSK-3β) Inhibitor, Combined with Retifanlimab, a PD-1 Inhibitor, Plus Modified FOLFIRINOX As Frontline Therapy for Patients with Advanced Pancreatic Adenocarcinoma (RiLEY)

This is a study of the combination of 9 ING-41 (elraglusib) and retifanlimab plus mFOLFIRINOX in patients with pancreatic cancer without prior systemic therapy for advanced disease. The safety lead-in cohort will consist of 6 patients, followed by dose de-escalation if necessary, based on safety assessments. After evaluating the safety and tolerability at the initial dose level, the study will proceed to an expansion cohort at the determined safe dose level, with the total maximum enrollment not exceeding 12 patients for the entire study.

开始日期2025-05-31

申办/合作机构

University of Pittsburgh

[+2]

NCT05077800

/ Recruiting临床2期IIT

A Phase II Study of FOLFIRINOX Combined With the Glycogen Synthase Kinase-3 Beta (GSK-3 β) Inhibitor 9-ING-41 and the Transforming Growth Factor-β (TGF-β) Inhibitor Losartan in Patients With Untreated Metastatic Pancreatic Cancer

The purpose of this study is to find out if an experimental drug will prevent metastatic pancreatic adenocarcinoma from becoming resistant to standard treatment for the disease.
The names of the study drugs involved in this study are:
* 9-ING-41
* Losartan
* Ferumoxytol
* FOLFIRINOX (made up of 4 different drugs):
* 5-Fluorouracil (5-FU)
* Oxaliplatin
* Irinotecan
* Leucovorin

开始日期2022-03-21

申办/合作机构

The Massachusetts General Hospital

[+2]

100 项与 Elraglusib 相关的临床结果

登录后查看更多信息

100 项与 Elraglusib 相关的转化医学

登录后查看更多信息

100 项与 Elraglusib 相关的专利（医药）

登录后查看更多信息

项与 Elraglusib 相关的文献（医药）

2025-06-01·ESMO Open

Phase II study of elraglusib (9-ING-41), a GSK-3β inhibitor, in combination with gemcitabine plus nab-paclitaxel in previously untreated metastatic pancreatic cancer

Article

作者: Giles, F J ; Davis, E J ; Weisskittel, T ; Raufi, A G ; Mahalingam, D ; Steeghs, N ; Cervantes, A ; Carneiro, B A ; Huerta, M ; Mulcahy, M ; Mazar, A P ; Berlin, J ; Ugolkov, A ; Powell, S F ; Smith, S ; Mikrut, W ; Sahai, V ; Coveler, A L ; Saeed, A ; Cavalcante, L

INTRODUCTION:

The purpose of this study was to assess the efficacy and safety of elraglusib (9-ING-41), a GSK-3β inhibitor, in combination with gemcitabine/nab-paclitaxel (GnP) in previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC).

MATERIAL AND METHODS:

In a nonrandomized, Simon's two-stage, phase II study, patients with mPDAC received elraglusib 15 mg/kg on days 1 and 4 each week and GnP on days 1, 8, and 15 in a 28-day cycle. The primary endpoint was disease control rate (DCR); secondary endpoints were objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and treatment-emergent adverse events (TEAEs).

RESULTS:

A total of 42 patients, who were enrolled and treated, had a median age of 67 years and were 57.1% male. Overall, 38 patients received elraglusib at 15 mg/kg and 4 at 9.3 mg/kg with GnP. DCR was 35.7% [95% confidence interval (CI) 21.6% to 52.0%], and ORR was 26.2%. The median PFS and OS were 5.4 months (95% CI 4.4-9.2 months) and 11.9 months (95% CI 7.8-16.5 months), respectively. Most common TEAEs were visual impairment (83.3%), fatigue (69%), and nausea (66.7%). Grade ≥3 TEAEs occurred in 85.7% of patients and included neutropenia (52.4%), leukopenia (42.9%), and fatigue (21.4%). The dose of elraglusib was reduced to 9.3 mg/kg due to increased exacerbation of GnP-related toxicities and frequent dose interruptions and reductions of elraglusib.

CONCLUSIONS:

Elraglusib/GnP showed preliminary clinical activity. In terms of safety, elraglusib resulted in a modest exacerbation of GnP-related toxicities, leading to a dose reduction of elraglusib to 9.3 mg/kg twice a week. Based on the initial efficacy and safety data, the study was amended to a randomized phase II study that will evaluate the 9.3 mg/kg dose.

2024-12-01·European Journal of Haematology

A New Strategy for Adult T‐Cell Leukemia Treatment Targeting Glycogen Synthase Kinase‐3β

Article

作者: Ishikawa, Chie ; Mori, Naoki

ABSTRACT:

Objectives:

The role of glycogen synthase kinase (GSK)‐3β in adult T‐cell leukemia (ATL) caused by human T‐cell leukemia virus type 1 (HTLV‐1) is paradoxical and enigmatic. Here, we investigated the role of GSK‐3β and its potential as a therapeutic target for ATL.

Methods:

Cell proliferation/survival, cell cycle, apoptosis, and reactive oxygen species (ROS) generation were examined using the WST‐8 assay, flow cytometry, and Hoechst 33342 staining, respectively. Expression of GSK‐3β and cell cycle/death‐related proteins, and survival signals was analyzed using RT‐PCR, immunofluorescence staining, and immunoblotting.

Results:

HTLV‐1‐infected T‐cell lines showed nuclear accumulation of GSK‐3β. GSK‐3β knockdown and its inhibition with 9‐ING‐41 and LY2090314 suppressed cell proliferation/survival. 9‐ING‐41 induced G2/M arrest by enhancing the expression of γH2AX, p53, p21, and p27, and suppressing the expression of CDK1, cyclin A/B, and c‐Myc. It induced caspase‐mediated apoptosis by decreasing the expression of Bcl‐xL, Mcl‐1, XIAP, c‐IAP1/2, and survivin, and increasing the expression of Bak and Bax. 9‐ING‐41 also induced ferroptosis and necroptosis, promoted JNK phosphorylation, and suppressed IKKγ and JunB expression. It inhibited the phosphorylation of IκBα, Akt, and STAT3/5, induced ROS production, and reduced glycolysis‐derived lactate levels.

Conclusion:

GSK‐3β functions as an oncogene in ATL and could be a potential therapeutic target.

2024-11-01·Cancer research communications

Elraglusib Induces Cytotoxicity via Direct Microtubule Destabilization Independently of GSK3 Inhibition

Article

作者: Sutherland, Calum ; Tanaka, Tomoyuki U. ; Saurin, Adrian T. ; Li, Shuyu ; Tauro, Sudhir ; Coats, Josh T.

Abstract:

Elraglusib (9-ING-41) is an ATP-competitive inhibitor of glycogen synthase kinase-3 (GSK3) with preclinical studies demonstrating broad activity against many tumor types. Promising early-phase clinical trial data led to FDA orphan drug status, and a randomized phase II study in combination with cytotoxic chemotherapy in pancreatic cancer has recently completed its recruitment. Similarly, single-agent responses in adult T-cell leukemia/lymphoma and melanoma and combination treatment data in several other tumor types have been encouraging. The elraglusib mechanism of action is unknown, but it is unlikely to act through GSK3 inhibition because cytotoxicity is observed below the IC50 for GSK3, and other small molecule GSK3 inhibitors do not produce cytotoxic effects, at least in lymphoma cells. We show here that elraglusib perturbs chromosomal alignment to cause a mitotic arrest in multiple tumor lines. This arrest is caused by direct microtubule (MT) depolymerization, which prevents the attachment of kinetochores to MTs. At clinically relevant doses, these mitotically arrested cells eventually undergo mitotic slippage, leading to gross chromosome missegregation, DNA damage, and apoptosis. These effects explain the cytotoxicity of elraglusib because temporarily pausing cell-cycle progression with the CDK4/6 inhibitor palbociclib abolishes any drug-induced genotoxicity and apoptosis. In summary, elraglusib acts as a direct MT destabilizer both in vitro and across multiple cancer types, resulting in mitotic arrest, DNA damage, and apoptosis. These effects likely account for its broad pan-cancer activity, which does not rely upon GSK3 inhibition as they are not replicated by other GSK3 inhibitors.

Significance::

Elraglusib was designed as a GSK3 inhibitor and is currently in clinical trials for several cancers. We show conclusively that the target of elraglusib that leads to cytotoxicity is MTs and not GSK3. This has significant implications for ongoing clinical trials of the compound and will help in understanding off-target side effects, inform future clinical trial design, and facilitate the development of biomarkers to predict response.

项与 Elraglusib 相关的新闻（医药）

2025-08-07

·GlobeNewswire-Health Care

Actuate Therapeutics To Collaborate with Incyte Corporation and the University of Pittsburgh on Clinical Trial of Elraglusib in Combination with Retifanlimab and mFOLFIRINOX in Patients with Advanced Pancreatic Cancer

Clinical Trial Study to be Conducted at UPMC Hillman Cancer to Evaluate Novel Combination as Frontline Therapy Aug. 06, 2025 -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced the initiation of the Phase 1b trial of elraglusib in combination with Incyte’s PD-1 inhibitor, retifanlimab, and modified FOLFIRINOX (mFOLFIRINOX) as frontline therapy in advanced pancreatic adenocarcinoma. The trial is being conducted in collaboration with UPMC Hillman Cancer Center and Incyte Corporation. The Investigator-Initiated Phase 1b open-label, single-arm RiLEY (NCT06896188) trial, led by Anwaar Saeed, MD, Associate Professor of Medicine, and Chief of the Gastrointestinal Medical Oncology at UPMC Hillman Cancer Center, will initially enroll up to 12 patients with advanced pancreatic adenocarcinoma with an expansion plan based on interim efficacy results. The primary objective of the trial is to determine the recommended phase 2 dose (RP2D) for the combination regimen, while the secondary objectives include evaluation of overall response rate (ORR), disease control rate (DCR), median progression-free survival (mPFS), overall survival (OS), and assessment of safety and tolerability. “We are very excited to launch this study of elraglusib combined with retifanlimab and mFOLFIRINOX as a potentially synergistic, immune-modulatory approach for patients with advanced pancreatic cancer,” said Anwaar Saeed, MD, study principal investigator. “While the first generation of immune checkpoint (PD-1, PDL-1, CTLA-4) inhibitors, including retifanlimab, has been transformative by targeting key immune pathways and restoring anti-cancer effector cells activity, this study explores complementary mechanisms - particularly those evoked by elraglusib - that may modulate additional checkpoints and work synergistically with existing inhibitors to deepen and broaden anti-tumor responses. A growing body of preclinical and clinical data suggests that elraglusib can stimulate NK/T-cell anticancer effector functions, enhance antigen presentation, and reduce myeloid-derived suppressor cells in the tumor. These effects have been observed in the context of emerging clinical activity in metastatic pancreatic cancer.” In a recent Phase 2 study, elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) in first-line metastatic pancreatic adenocarcinoma (mPDAC) met its primary endpoint, showing a significant increase in median overall survival, a 37% reduction in the risk of death, and a doubling of the 12-month survival rate. In addition, increased CD8-positive and granzyme B-positive T cells, increased NK cells, and decreased myeloid-derived suppressor cells were observed in tumor biopsies only from elraglusib-treated patients, demonstrating elraglusib’s proposed immune modulating mechanism of action in patients with mPDAC. “We believe the combination of elraglusib with retifanlimab and mFOLFIRINOX represents a novel and mechanistically compelling strategy to address unmet needs in advanced pancreatic adenocarcinoma,” said Daniel Schmitt, President & Chief Executive Officer of Actuate. “The collaboration with UPMC Hillman Cancer Center and Incyte enables us to explore new synergistic opportunities for patients who have not yet received systemic therapy and builds on the momentum of our ongoing clinical programs. The study further allows us to assess ways to optimize elraglusib’s potential through a complementary multi-agent approach designed to enhance both efficacy and durability of response.” In addition, elraglusib is being studied in a separate investigator initiated Phase 2 (NCT05077800) trial in combination with FOLFIRINOX and losartan in treatment-naïve mPDAC patients. Initial data from this Phase 2 trial, which were presented at the American Association for Cancer Research (“AACR”) Special Conference on Advances in Pancreatic Cancer Research last September, showed patients with extensive liver metastases experienced deep, durable responses to the novel combination treatment. Additional results from that study are expected in 2026. Actuate is a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers. Actuate’s lead investigational drug, elraglusib (a novel GSK-3β inhibitor), targets molecular pathways in cancer that are involved in promoting tumor growth and resistance to conventional cancer drugs such as chemotherapy through the inhibition of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) and DNA Damage Response (DDR). Elraglusib may also mediate anti-tumor immunity through the regulation of multiple immune checkpoints and immune cell function. The content above comes from the network. if any infringement, please contact us to modify.

临床结果免疫疗法AACR会议

2025-07-21

·GlobeNewswire-Health Care

Actuate Therapeutics Advances Clinical Program in Ewing Sarcoma After Positive Phase 1 Trial Demonstrates Complete and Partial Responses in Difficult-to-Treat Pediatric Sarcomas

- Announces Completion of Phase 1 Study of Elraglusib in Pediatric Patients - Prolonged and Durable Complete Responses (CRs) Observed in Two of Ten Refractory Ewing Sarcoma Patients - Two Additional Patients Had Durable Stable Disease in Notoriously Difficult-to-Treat Cancer - Confirmed Partial Response (PR) in a patient with a desmoplastic small-round-cell tumor (DSRCT) - Company Initiating Planning of Phase 2 Trial of Elraglusib in Children, Adolescents, and Adults with Refractory/Resistant Ewing Sarcoma July 17, 2025 -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced the end of the Phase 1 portion of its clinical study evaluating elraglusib monotherapy or in combination with irinotecan, irinotecan plus temozolomide, or with cyclophosphamide plus topotecan in pediatric patients with refractory malignancies (Actuate-1902). Following encouraging signals of activity, particularly in treatment-refractory Ewing Sarcoma (EWS), a small round cell sarcoma that forms in soft tissue and bone, the Company will seek to advance the clinical development program towards a Phase 2 study in children, adolescents, and adults with relapsed/refractory EWS. “Refractory and resistant EWS is one of the most aggressive and underserved cancers affecting children and young adults with very low survival rates,” said Dr. Andrew Mazar, Actuate’s Scientific Co-founder and Chief Operating Officer. “To observe complete responses in this setting is highly unexpected, and these exceptional early results position elraglusib as a potential first-in-class therapy option in an indication where no approved targeted therapies currently exist.” The Phase 1/2 Trial (NCT 04239092), also referred to as Actuate-1902, was an open-label, multicenter study evaluating the safety and efficacy of elraglusib in pediatric patients with relapsed/refractory malignancies, including EWS and other pediatric sarcomas. To date, the study has enrolled ten (10) patients with relapsed/refractory EWS (>1 remission) treated with the combination of elraglusib and topotecan/cyclophosphamide. “We are highly encouraged by the responses observed in refractory and resistant EWS, a disease where treatment options are extremely limited beyond frontline chemotherapy,” said Daniel Schmitt, President & Chief Executive Officer of Actuate. “With these promising clinical signals in hand, we are advancing our development plans focused on EWS by pursuing a Phase 2 trial and plan to meet with regulators to discuss potential registration path in this indication.” Of the ten (10) EWS patients enrolled, two (2) patients achieved complete responses by CT and/or complete metabolic responses (CR/CMR), while two (2) had confirmed stable disease. A partial response (PR) was also observed in one patient with a desmoplastic small-round-cell tumor (DSRCT), a small round cell sarcoma that forms in soft tissue. While the sample size specific to Ewing Sarcoma in the 1902 study was small, the responses are viewed as positive evidence of anti-tumor activity in this difficult-to-treat indication, and Actuate plans to further investigate elraglusib’s ability to positively change patients’ potential for successful treatment in a Phase 2 trial in pediatric, adolescent, and adult patients with relapsed/refractory Ewing Sarcoma. The Company is collaborating with key opinion leaders and consortiums with interest in EWS to ensure the design of the upcoming study aligns with both patient needs and regulatory expectations. The Company expects to initiate the trial in 2026, subject to available funding. Ewing sarcoma (EWS) is a highly metastatic form of sarcoma with a peak incidence at the age of 15, that ranks as the second most prevalent primary malignant tumor of childhood and adolescence. Approximately 25% of new EWS patients have metastatic disease when first diagnosed, which is the most significant predictor of poor survival. Actuate is a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers. Actuate’s lead investigational drug, elraglusib (a novel GSK-3β inhibitor), targets molecular pathways in cancer that are involved in promoting tumor growth and resistance to conventional cancer drugs such as chemotherapy through the inhibition of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) and DNA Damage Response (DDR). Elraglusib may also mediate anti-tumor immunity through the regulation of multiple immune checkpoints and immune cell function. The content above comes from the network. if any infringement, please contact us to modify.

临床结果

2025-06-30

·癌度

《癌度早报2025年6月30日》

临床试验病友交流群（点击）一、新药快讯1、靶向叶酸受体的抗体偶联药，85%的卵巢癌患者病灶缩小mirvetuximab soravtansine是一款靶向药叶酸受体α（FRα）的抗体偶联药，已经获得美国FDA批准用于治疗FRα阳性、铂类耐药的上皮性卵巢癌、输卵管癌或原发性腹膜癌。在一项国际临床试验中，79名铂敏感复发性且FRα阳性卵巢癌患者，51.9%的患者病灶大幅度缩小，6人病灶完全消失，出现病灶缩小的患者比例占到了85%，患者的中位生存时间达到了27.2个月，而且不管HRD指标如何，使用这款药的治疗效果都不错。即便是之前使用了很多药物的患者，依然能从该药治疗里获益。2、伏美替尼治疗EGFR基因PACC突变，展现良好治疗效果EGFR基因的PACC突变包括G719X、L747X、S768I、L792X和T854I等罕见突变，占到了EGFR所有突变的12.5%，根据最近的一项IB期临床试验，靶向药伏美替尼在未经治疗的、携带EGFR基因PACC突变的非小细胞肺癌展现良好疗效，160毫克剂量组43.5%的患者病灶显著缩小或完全消失，240毫克剂量组则有68.2%的患者病灶显著缩小或完全消失。中位无进展生存期为16个月，53%患者脑转移病灶显著缩小或完全消失，41%的患者脑病灶全消失。3、胰腺癌治疗新药Elraglusib，联合化疗可降低死亡风险43%根据一项二期临床试验，一款英文名称为Elraglusib的前沿药联合化疗，也就是吉西他滨和白蛋白紫杉醇，相比单独使用化疗，对于刚确诊未使用任何系统治疗的晚期胰腺癌患者，将死亡风险下降了43%。单独化疗的疾病控制率为44.8%，而联合治疗的疾病控制率为53.4%，治疗应答率方面两组患者分别是37.9%和29.3%，中位无进展生存期也是实验组更长，化疗组仅为5.6个月，而实验组是6.9个月。而且对于肝转移的胰腺癌患者Elraglusib与化疗联合获益更明显。二、抗癌前沿1、人工智能时代，AI能看片、诊断、解读基因检测报告且预测疗效目前AI系统在识别良性和恶性肿瘤方面显示出潜力，甚至是可以通过影像预测肿瘤基因突变，尤其是EGFR和ALK突变，能通过影像学检查识别基因突变特征，PD-L1表达也能预测。另外有研究团队使用神经网络可以实现肺癌的亚型分类，已经接近病理医生的诊断水平。目前还有研究团队研究数据模型来预测肺癌患者的生存情况，比如预测患者对化疗的反应情况。还有AI模型结合临床和影像组学数据，准确预测了晚期非小细胞肺癌的生存情况。

临床2期临床结果

100 项与 Elraglusib 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB16047

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
转移性胰腺导管腺癌	临床2期	美国	Mayo Clinic	2025-05-30
转移性黑色素瘤	临床2期	美国	Actuate Therapeutics, Inc.	2023-05-31
转移性黑色素瘤	临床2期	美国	Lantern Pharma, Inc.	2023-05-31
转移性胰腺癌	临床2期	美国	Actuate Therapeutics, Inc.	2022-03-21
转移性胰腺腺癌	临床2期	美国	Actuate Therapeutics, Inc.	2022-03-21
转移性骨肉瘤	临床2期	美国	Actuate Therapeutics, Inc.	2022-03-01
小细胞肉瘤	临床2期	美国	Actuate Therapeutics, Inc.	2022-03-01
晚期胰腺腺癌	临床2期	美国	Actuate Therapeutics, Inc.	2022-01-26
晚期胰腺腺癌	临床2期	美国	Incyte Corp.	2022-01-26
胰腺导管腺癌	临床2期	美国	Actuate Therapeutics, Inc.	2022-01-26

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04239092 (Actuate-1902, GlobeNewswire) 人工标引	临床1期	肉瘤 \| 尤文肉瘤	10	elraglusib	醖積願願襯網遞獵憲選(築蓋蓋網鬱淵鹽簾選遞) = 齋築鹹鹹艱廠餘顧鏇鬱艱製繭遞願構範齋顧衊 (選壓壓餘顧膚齋鏇獵範 ) 更多	积极	2025-07-17
NCT05239182 (RiLEY, CTgov)	临床2期	胰腺腺癌 \| 胰腺导管腺癌 \| 晚期胰腺腺癌	7	9-ING-41+Abraxane+Gemcitabine+Retifanlimab	構簾鏇膚繭齋夢繭廠選 = 淵範遞糧鹽製範製廠膚築鹽選廠鏇憲夢餘艱鬱 (獵鏇築壓鏇夢構選鏇夢, 繭膚廠鬱壓齋襯網鹽選 ~ 襯糧觸製蓋窪鹽選製簾) 更多	-	2025-07-17
NCT03678883 (1801 part 3B, ASCO2025)	临床2期	转移性胰腺导管腺癌 CA 19-9 levels \| IFNβ \| PD-L1	-	Elraglusib 9.3 mg/kg IV once weekly + Gemcitabine/nab-paclitaxel	淵夢範醖製壓膚鬱願製(餘夢鑰鏇網鏇積鬱艱淵) = 網壓憲廠繭齋繭糧窪顧窪淵獵窪襯糧窪獵餘鑰 (壓繭膚淵積遞構獵壓範 ) 更多	积极	2025-05-30
				Gemcitabine/nab-paclitaxel	淵夢範醖製壓膚鬱願製(餘夢鑰鏇網鏇積鬱艱淵) = 築範艱簾願齋壓鑰膚淵窪淵獵窪襯糧窪獵餘鑰 (壓繭膚淵積遞構獵壓範 ) 更多
NCT03678883 (Actuate-1801 Part 3B, GlobeNewswire) 人工标引	临床2期	转移性胰腺癌一线	-	elraglusib + gemcitabine/nab-paclitaxel (GnP)	鑰糧遞構醖襯選積鏇壓(醖艱簾鬱襯膚憲餘製鬱) = elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) met the primary endpoints and achieved statistical significance in topline results. 糧選築獵觸願壓鑰齋顧 (獵製網襯鏇鏇憲鹹遞鹹 ) 达到	积极	2025-05-09
				gemcitabine/nab-paclitaxel (GnP)
NCT05010629 (AACR2025)	临床2期	唾液腺肿瘤 tumor PD-L1 \| GSK-3β expression	32	Elraglusib	鹹網選膚鹹觸簾艱鹹齋(網簾鏇蓋衊衊壓壓選憲) = 衊構繭襯憲鹽鏇選糧齋願簾醖齋齋鏇糧糧淵觸 (繭壓壓淵選衊窪鹹遞鏇, 2 ~ 25) 更多	积极	2025-04-29
NCT04239092 (Actuate-1801, GlobeNewswire) 人工标引	临床2期	胰腺癌一线	286	Elraglusib + gemcitabine/nab-paclitaxel	餘顧糧願糧鬱鑰鏇鹽製(遞襯窪構餘襯遞艱窪廠) = 製膚衊願蓋壓鹹築鹽鬱遞憲壓觸繭鹽衊顧糧衊 (構鏇齋糧觸窪壓積糧齋 ) 达到更多	积极	2024-12-17
				gemcitabine/nab-paclitaxel	餘顧糧願糧鬱鑰鏇鹽製(遞襯窪構餘襯遞艱窪廠) = 鑰襯窪製鬱醖壓獵鬱構遞憲壓觸繭鹽衊顧糧衊 (構鏇齋糧觸窪壓積糧齋 ) 达到更多
NCT04239092 (GlobeNewswire) 人工标引	临床1/2期	尤文肉瘤 \| 促纤维增生性小圆细胞瘤	8	elraglusib	獵淵網憲夢範製獵膚繭(鹹觸憲繭願齋選鬱餘襯) = 廠遞膚艱鏇網襯觸淵衊壓廠顧構網顧廠鹽顧窪 (願鬱膚選淵網選鏇製醖 ) 更多	积极	2024-09-09
NCT03678883 (ASCO 12023 \| ASCO 22023) 人工标引	临床2期	晚期胰腺导管腺癌	42	gemcitabine+Albumin-Bound Paclitaxel+Elraglusib	壓構鑰廠願鑰醖醖廠餘(襯衊鬱築夢襯餘繭襯艱) = 觸遞鑰襯淵鹽鏇壓餘餘遞鬱繭鹽淵積夢觸艱糧 (顧築遞醖蓋鬱築獵觸齋, 32.5 ~ 70.6) 更多	积极	2023-05-26
NCT03678883 (AACR2023) 人工标引	临床1/2期	晚期癌症三线	-	elraglusib (melanoma)	鑰糧廠鹹鑰獵襯憲壓窪(觸範夢壓獵醖夢襯窪醖) = 醖獵鹹窪鑰網憲鏇觸憲遞遞觸蓋齋齋齋齋範齋 (鏇獵夢構廠襯顧鬱壓鹽 )	积极	2023-04-14
				elraglusib (colorectal cancer)	蓋衊繭齋糧廠構積鹹衊(膚夢網憲觸壓壓顧壓廠) = 壓簾夢獵製獵淵鹽窪獵簾鹹繭壓襯糧網窪膚夢 (窪鹽齋鹽膚繭窪遞繭廠 ) 更多
NCT04239092 (ASCO2022) 人工标引	临床1/2期	肿瘤	23	ElraglusibElraglusib alone or in combination with chemotherapy	網鹽顧觸衊繭簾窪餘糧(鬱製鹹廠糧淵糧窪遞鑰) = none 築觸範憲餘獵願廠範糧 (壓鬱憲淵蓋獵淵鹹衊鏇 ) 更多	积极	2022-06-02
				Elraglusib + cyclophosphamide/topotecan or irinotecan